19 results about "Itraconazole" patented technology

Disclosed herein are analogues of itraconazole that are potent hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

This invention discloses a screening method for inhibitors of the interaction between ATF3 and Importin α and its application. By constructing a target model based on the interaction interface between Importin α and ATF3, this target model is used to perform virtual screening of a small molecule compound library based on molecular docking, and the binding free energy is calculated to screen for candidate compounds that can bind to Importin α and effectively block its interaction with ATF3. The effects of the candidate compounds on the interaction between Importin α and ATF3 are verified through in vivo and / or in vitro experiments. This invention has screened and obtained several small molecule candidate drugs, with itraconazole as a representative small molecule compound, capable of inhibiting the interaction between Importin α and ATF3.

The present disclosure relates to methods of treating cancer, such as lung cancer (e.g., non-small cell lung cancer) by administering a dry powder to the respiratory tract of a subject in need thereof (e.g., by oral inhalation), the dry powder comprising respirable dry particles that comprise an angiogenesis inhibitor (e.g., itraconazole), and optionally a stabilizer (e.g., polysorbate 80) and / or one or more excipients (e.g., leucine and a sodium salt, such as sodium sulfate).

The invention belongs to the technical field of medicines, and particularly relates to itraconazole transdermal cream and a preparation method thereof. According to the itraconazole transdermal cream provided by the invention, the itraconazole and the clove essential oil are jointly applied by adopting an emulsification method, the limitation of single use of the itraconazole and the clove essential oil is broken through, the bioavailability of the itraconazole and the clove essential oil is improved, and the itraconazole transdermal cream acts on an infected part after being subjected to transdermal absorption through local administration, so that the itraconazole is absorbed into blood and reaches the skin of the whole body to play a role; the traditional Chinese medicine composition can achieve the same blood concentration and effect of oral administration, is convenient to use, reduces liver toxicity and gastrointestinal tract adverse reactions, and reduces the risk of adverse reactions and drug interaction at the same time.

The application discloses a kind of containing it is the preparation method of spray and preparation method of eucalyptol for external use, and each 1000ml external use spray material composition: it is 8~10g, eucalyptol 10~20g, hydroxypropyl-β-cyclodextrin 250~300g, propylene glycol 100~140g, 9.5~12g of hydrochloric acid, diethylene glycol monoethyl ether 140~160g, caprylic acid capric acid polyethylene glycol glyceride 40~60g, 1.9~2.1g of sodium hydroxide, the rest is pure water, and preparation is obtained external use spray, mass is stable, antifungal effect is remarkable, clinical use is convenient.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by the parasite Trypanosoma cruzi known as Chagas disease. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Chagas disease, or in an amount effective to prevent Chagas disease in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The form of itraconazole used in the pharmaceutical composition may be prepared by any suitable process wherein the active ingredients to have sufficient bioavailability when injected into a human or animal subject. The long-term method for treating or preventing Chagas disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Chagas disease than previously possible.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by Leishmania species parasites such as Leishmaniasis. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Leishmaniasis, or in an amount effective to prevent Leishmaniasis in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The long-term method for treating or preventing Leishmania disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Leishmaniasis than previously possible.

Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier. The one or more anti-fungal agents may include, for example, terbinafine HCl, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.

The invention discloses a biocompatible antibacterial composite material and a preparation method thereof. The biocompatible antibacterial composite material is prepared from N-isopropylacrylamide and a vinyl proline choline ionic liquid monomer, or the N-isopropylacrylamide, acrylic acid and the vinyl proline choline ionic liquid monomer through free radical polymerization. According to the invention, the obtained aerogel is immersed in an itraconazole (ITR)-loaded solution or an ibuprofen-loaded solution, the obtained drug-loaded gel is freeze-dried again, the drug-loaded effect is observed, and a drug dissolution experiment is carried out. The crystallinity of the medicine in the medicine-loaded composite material is observed through an XRD technology, and the result clearly shows that the medicine is kept in an amorphous state. The preparation method is simple and easy to implement, and the prepared composite material has a wide application prospect in the field of biomedicine.

The invention belongs to the technical field of new application of medicines, and particularly relates to application of itraconazole in preparation of a product for amplifying an induced T cell into a central memory T cell in vitro. It is found through experiments that itraconazole is additionally added into a CAR-T cell culture medium, CAR-T cells can be rapidly induced, differentiated and amplified into central memory CAR-T cells in vitro, and the proportion of the central memory CAR-T cells in the CAR-T cells is obviously increased. Itraconazole is a clinical medicine, pharmacokinetic and toxicological studies are clear, the safety is high, good technical support is provided for tumor cell treatment, and the itraconazole has important significance.

The invention discloses an itraconazole solid dispersion with high drug loading capacity. The itraconazole solid dispersion is prepared from the following components in percentage by weight: 40-55% of itraconazole, 40-55% of a polymer carrier and 2-6% of a crystallization inhibitor, the polymer carrier is selected from one or a combination of at least two of hydroxypropyl methylcellulose, copovidone and a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; the crystallization inhibitor is selected from one or a combination of at least two of lauryl sodium sulfate, poloxamer and polysorbate. According to the itraconazole solid dispersion, itraconazole is highly dispersed in the polymer carrier, so that the dissolution rate of itraconazole in the solid dispersion is further improved on the basis of ensuring that the raw materials are stable and are not degraded; the crystallization inhibitor such as lauryl sodium sulfate is used for effectively inhibiting the recrystallization and easy aging and dissolution rate reduction behaviors of itraconazole in the storage process of the high-drug-loading-capacity solid dispersion.

This invention belongs to the field of pharmaceutical powder formulations, and relates to an itraconazole inhalation dry powder, its preparation method, and its application. The preparation involves preparing itraconazole cocrystals via solvent evaporation, then forming a cocrystal nano-suspension through media milling. The nano-suspension is mixed with an excipient and then spray-dried to prepare the dry powder. The dry powder composition of this invention has spherical particles with an aerodynamic diameter of less than 4 μm. It exhibits an air displacement rate greater than 90%, a fine particle fraction greater than 40%, rapid dispersion after in vitro atomization, and good localization effect in the lungs in vivo.

The application belongs to the technical field of new use of medicines, and particularly relates to application of itraconazole in preparation of a product for inducing T cells to be central memory T cells in vitro. It is found through experiments that, by additionally adding itraconazole in a CAR-T cell culture medium, CAR-T cells can be rapidly induced and differentiated to be central memory CAR-T cells in vitro, and the proportion of the central memory CAR-T cells in the CAR-T cells is obviously increased. Itraconazole is a clinical drug, and pharmacokinetics and toxicology research is clear, and the safety is high. The application provides good technical support for tumor cell treatment, and has important significance.

The present invention relates to a triazole drug suspension, a preparation method therefor, and use thereof. The triazole drug suspension of the present invention comprises a therapeutically effective amount of itraconazole, a surfactant, solvent water, an osmotic pressure regulator, a metal complexing agent, and a pH regulator, wherein the mass ratio of itraconazole to the surfactant is 5:1-15:1. Itraconazole has a D10 particle size of greater than or equal to 0.5 μm, a D50 particle size of 1.5-3.5 μm, and a D90 particle size of less than or equal to 6.0 μm. The concentration of free itraconazole in the suspension is not less than 0.04 μg / ml. The suspension of the present invention has a suitable free-state drug content and a suitable granular drug particle size distribution, enabling, after the suspension of the present invention is administered by means of inhalation, the drug to be rapidly absorbed by a target part and to act, and maintaining sustained and slow release. While a therapeutic dose is maintained, the frequency of administration is reduced, thereby improving the safety of drug administration.

Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

The invention relates to the technical field of biology, in particular to a primer pair, a primer probe composition, a PCR premix, a kit and a method for detecting multiple respiratory pathogens. The invention discloses a primer pair with nucleic acid sequences as shown in SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38 and 40-41. Aiming at a target respiratory pathogen, a specific amplification primer pair is designed and is matched with a proper probe, so that eight-target joint detection can be realized, and the influence of heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, epinephrine and lidocaine hydrochloride in a detection sample can be avoided in the detection process; the anti-interference performance is good, and cross reaction with rhodococcus equi, candida tropicalis and candida krusei does not exist.

Provided is a pharmaceutical composition comprising an effective amount of itraconazole, and a pharmaceutically acceptable excipient. The use of the pharmaceutical composition for treatment of idiopathic pulmonary fibrosis is also provided.

The invention provides an oral solution capable of obviously improving the palatability of cats and good in stability and a preparation method of the oral solution. The oral solution comprises the following raw materials: 1%-2% of itraconazole, 35%-45% of hydroxypropyl beta-cyclodextrin, 10%-15% of propylene glycol, 20%-30% of an amorphous sorbitol solution, 1%-1.5% of vitamin C, 0.1%-1% of essence, 0.01%-0.025% of sucralose, a proper amount of a pH regulator and the balance of purified water; the traditional cognition that cats do not have sweetness perception, so that sweeteners are invalid is broken through, the bitterness of itraconazole and the acerbity of a solution are remarkably covered through compounding of specific components, the adverse reaction rate after the cats take the itraconazole is reduced, and the medication compliance is improved to 90% or above; components with dual functions are introduced, so that the flavoring is assisted, the hydrolysis and oxidative degradation of itraconazole can be inhibited, the solution is ensured to keep high quality under the conditions of high temperature and accelerated storage, and the validity period is prolonged.